Is tesamorelin banned in sport? WADA status

Yes. Tesamorelin is prohibited in sport. The World Anti-Doping Agency (WADA) classifies tesamorelin under section S2 of its Prohibited List, the section covering peptide hormones, growth factors, growth hormone secretagogues, and mimetics^[1]. The prohibition applies in competition and out of competition, across every sport governed by the WADA Code. That means the ban is year-round, not just on race day or matchday.

What section S2 covers and why tesamorelin is in it

Section S2 of the WADA Prohibited List targets substances that act on the growth hormone axis. It names several specific growth hormone releasing factors, and it extends to any agent with a similar chemical structure or similar biological effect to those named^[1]. Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the pituitary gland to release growth hormone in pulses. It binds the GHRH receptor and triggers endogenous growth hormone release, which is precisely the mechanism S2 targets.

A 2021 paper by Memdouh and colleagues in Drug Testing and Analysis confirms this directly: "the administration of growth hormone releasing hormone (GHRH) and its synthetic analogs is prohibited by the World Anti-Doping Agency." The authors developed a detection method for four GHRH analogues, specifically sermorelin, tesamorelin, CJC-1295, and CJC-1295 with drug-affinity complex, in anti-doping samples^[2]. Tesamorelin is named in the analytical anti-doping literature precisely because it is a targeted substance.

Named substance versus catch-all: where tesamorelin sits

The brief notes a distinction that matters for athletes: the difference between substances listed by name in the Prohibited List text and substances caught by the catch-all language. The S2 section covers not only explicitly named GHRH-releasing factors but also any substance with a similar chemical structure or biological effect^[1]. Tesamorelin is a direct GHRH analogue. Whether a given year's printed list names it explicitly or relies on the catch-all language does not change the outcome for an athlete: the pharmacological mechanism places tesamorelin inside S2 in either case.

Athletes have sometimes assumed that a substance is permitted if it does not appear word-for-word in the list. That reasoning does not hold for S2. The section explicitly extends to related substances with similar biological effects, and GHRH receptor binding is the defining biological effect. Any substance that works the way tesamorelin works is covered.

The FDA approval complicates the TUE picture

Here is where tesamorelin differs from most peptides in this space. It is FDA-approved in the United States as Egrifta (and Egrifta SV) for one specific indication: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy^[3]. Most growth hormone secretagogues and GHRH analogues on S2 have no approved indication anywhere. Tesamorelin has one.

That creates a theoretical Therapeutic Use Exemption pathway. Under the WADA TUE framework, an athlete with a legitimate medical need for a prohibited substance may apply for a TUE to use it without sanction. The criteria require a genuine medical diagnosis, the absence of an equally effective permitted alternative, and that the treatment not confer a performance advantage beyond restoring the athlete to normal health. For an HIV-positive athlete with documented lipodystrophy who has exhausted other options, a TUE application for tesamorelin is at least arguable. Athletes in that situation should contact their national anti-doping organisation for guidance well before use, not after^[4].

The TUE picture for athletes without HIV-associated lipodystrophy is far narrower. Off-label tesamorelin use for body composition, anti-ageing, or other non-approved purposes does not carry the same medical foundation. A TUE application in that context would face the criterion that the substance is "necessary for the treatment of an acute or chronic medical condition" and that "no reasonable permitted therapeutic alternative exists." General body-composition goals would not satisfy those criteria.

Detection: tesamorelin can be found in samples

Prior to Memdouh and colleagues' 2021 work, GHRH synthetic analogues had not been detected in WADA-accredited laboratory samples despite being prohibited. Their paper filled that gap, developing a liquid chromatography-tandem mass spectrometry method that detected sermorelin, tesamorelin, CJC-1295, and CJC-1295 with DAC in urine, with limits of detection at or below WADA's required performance limit of 1 ng/mL^[2]. The analytical capability now exists. Athletes should not assume that historical gaps in detection represent a continuing low-risk window.

What the S2 ban does not depend on

The WADA prohibition on tesamorelin does not depend on evidence that it improves athletic performance. Section S2 targets substances with the mechanistic potential to elevate growth hormone and IGF-1, which are axes the Prohibited List addresses because elevated growth hormone was prohibited directly (section S2.1) well before the secretagogues were added. Tesamorelin's approved clinical effect, visceral fat reduction via the GHRH receptor, is consistent with the class mechanism the section targets. The ban is not conditional on a performance study.

Eric Topol, writing in Ground Truths in July 2025, grouped tesamorelin with CJC-1295 and ipamorelin as "growth hormone related peptides" that "carry the potential risk of cancer" on mechanistic grounds, through IGF-1 elevation^[5]. That concern is a separate matter from anti-doping status but points to the same growth hormone axis that makes the class a prohibited category.

What this article does not cover

This piece addresses tesamorelin's status under the WADA Code for competing athletes. It does not cover country-by-country regulatory status, whether tesamorelin is legal to import or possess outside of sport contexts, or the clinical evidence for the approved HIV-lipodystrophy indication. For the full regulatory and clinical picture, see the tesamorelin peptide page and the country regulation pages.

Competing athletes subject to the WADA Code who are prescribed tesamorelin for HIV-associated lipodystrophy should initiate a TUE application through their national anti-doping organisation before starting treatment. For the compounding-pharmacy regulatory picture in the US, the FDA approved Egrifta under NDA 022505; compounded tesamorelin is a separate product with its own lawfulness questions. The tesamorelin regulatory status section covers both the US authorisation and the 2012 EMA withdrawal in detail.

As with every peptide covered on this site: the decision to use tesamorelin in any context belongs to a clinician who knows your full medical and competition history. We explain the regulatory category. We do not advise on starting or stopping any medicine.